Featured Research

from universities, journals, and other organizations

Researchers Show Key Protein Necessary For Normal Development Of Red Blood Cells

Date:
October 4, 2005
Source:
Virginia Commonwealth University
Summary:
Virginia Commonwealth University researchers studying hemoglobin genes, mutations of which play a role in genetic blood disorders like sickle cell anemia and beta-thalassemia, have shown in studies with mice that the KLF2 protein is crucial for making young red blood cells.

The findings may point researchers to future gene therapies for patients with sickle cell anemia and beta-thalassemia.

Inthe October issue of Blood, the journal of the American Association forHematology, researchers demonstrated that a protein called KLF2regulates the production of embryonic globin genes and the maturationand stability of embryonic red blood cells in a mouse model.Researchers observed that KLF2 is responsible for controlling and“turning on” the embryonic globin gene.

“Understanding how genesare turned on and off, and the switch from the embryonic globin gene tothe adult beta-globin gene has clinical relevance to treatment ofsickle cell anemia and beta-thalassemia,” said Joyce A. Lloyd, Ph.D.,associate professor of Human Genetics at VCU, and corresponding authorfor this study.

“Our findings are significant for futuretreatment of these blood disorders, potentially using gene therapiesand other novel strategies,” she said. In gene therapy, a normal DNA isinserted into cells to correct a genetic defect. To correct the defector mutation, a gene may be replaced, altered or supplemented.

Accordingto Lloyd, the production of blood cells involves a complexdifferentiation pathway that involves the interaction of many molecularplayers and proteins.

In humans, there are four globin genesclustered on chromosome 11 in the order in which they are “turned on”or expressed. These genes include the epsilon-globin gene, twogamma-globin genes and the beta-globin gene. Lloyd said that duringfetal development, the embryonic epsilon-globin gene is active first,followed by the gamma-globin genes, and finally the adult form,beta-globin takes control following birth.

Lloyd and PriyadarshiBasu, Ph.D., lead investigator at VCU, and the research team comparedmice that were missing the gene for KLF2 to normal mice. They foundthat the KLF2-deficient mice produced embryonic red blood cells thatappeared abnormal, were more likely to undergo cell death, and producedsignificantly lower amounts of globin mRNA than those found in normalmice. Globin mRNA is a key player in gene expression that helpstranslate the DNA’s genetic code.

Lloyd and her colleaguesidentified that the role of KLF2 for the embryonic epsilon-globin genesis analogous to that of a protein called EKLF. EKLF plays a centralrole in the developmental regulation of the adult beta-globin gene, andis essential for the maturation and stability of adult red blood cells.Researchers believe that the roles of EKLF and KLF2 may partiallyoverlap in controlling human embryonic and fetal globin gene expression.

This research was supported by a grant from the National Institutes of Health.

Lloydcollaborated with colleagues in the VCU Department of Human Genetics,and the VCU Department of Anatomy and Neurobiology; the Department ofMolecular Genetics, Biochemistry and Microbiology at the University ofCincinnati; and the Department of Medicine at the University ofCalifornia-San Francisco.


Story Source:

The above story is based on materials provided by Virginia Commonwealth University. Note: Materials may be edited for content and length.


Cite This Page:

Virginia Commonwealth University. "Researchers Show Key Protein Necessary For Normal Development Of Red Blood Cells." ScienceDaily. ScienceDaily, 4 October 2005. <www.sciencedaily.com/releases/2005/10/051004175040.htm>.
Virginia Commonwealth University. (2005, October 4). Researchers Show Key Protein Necessary For Normal Development Of Red Blood Cells. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2005/10/051004175040.htm
Virginia Commonwealth University. "Researchers Show Key Protein Necessary For Normal Development Of Red Blood Cells." ScienceDaily. www.sciencedaily.com/releases/2005/10/051004175040.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins